UNDERWRITING AGREEMENT [●] Units, Each Consisting of One Share of Common Stock, One Warrant to Purchase One Share of Common Stock, and One Non-tradeable Warrant to Purchase One Share of Common StockUnderwriting Agreement • June 1st, 2023 • 60 Degrees Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
In addition, the Company shall pay the Representative an aggregate cash discount equal to eight percent (8%) of the aggregate sales price of securities sold in the Offering plus one and one-half percent (1.5%) of the aggregate sales price of securities sold in the Offering. In addition, the Company shall issue to the Representative that number of warrants equal to six percent (6%) of the number of securities of common stock sold in the Offering. In the event the Company engages the Representative in a private offering, the Company shall issue to the Representative that number of warrants equal to ten percent (10%) of the number of securities sold in such private offering.
COMMON STOCK PURCHASE WARRANTSecurity Agreement • June 1st, 2023 • 60 Degrees Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, <HOLDER>., or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that is one hundred eighty days (180) days after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the fifth year anniversary of the date of the IPO (the “Termination Date”) but not thereafter, to subscribe for and purchase from 60° Pharmaceuticals, Inc. (the “Company”), up to <WARRANT SHARES> shares of Common Stock (subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant issued pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) entered into as of the Initial Exercise Date between the Company and the initial Holder. The Ho
NOTE EXTENSION AGREEMENTNote Extension Agreement • June 1st, 2023 • 60 Degrees Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of May 18, 2023, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Maker”) and MOUNTJOY TRUST (the “Holder”).
NOTE EXTENSION AGREEMENTNote Extension Agreement • June 1st, 2023 • 60 Degrees Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of May 18, 2023, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Maker”) and GEOFFREY S. DOW REVOCABLE TRUST (the “Holder”).
NOTE EXTENSION AGREEMENTNote Extension Agreement • June 1st, 2023 • 60 Degrees Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of May 22, 2023, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Maker”) and BIGGER CAPITAL FUND, L.P. (the “Holder”).
NOTE EXTENSION AGREEMENTNote Extension Agreement • June 1st, 2023 • 60 Degrees Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of May 22, 2023, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Maker”) and CAVALRY INVESTMENT FUND, L.P. (the “Holder”).
NOTE EXTENSION AGREEMENTNote Extension Agreement • June 1st, 2023 • 60 Degrees Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of May 22, 2023, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Maker”) and WALLEYE OPPORTUNITIES MASTER FUND LTD. (the “Holder”).
